

Companies Featured

[000080.KS](#), [0002.HK](#), [0322.HK](#), [071050.KS](#), [0914.HK](#), [2020.HK](#),
[AEO.AX](#), [IIN.AX](#), [IMD.AX](#), [LEI.AX](#), [NCM.AX](#)

August 17, 2010

Asia/Pacific Morning Meeting Summary

Highlights

The Morning Call

Newcrest Mining (Australia) / Historically NCM Outperforms Gold in 2H of Year	Overweight
ANTA Sports Products (China) / 1H10 Beat on Margin; Maintain OW	Overweight
China Telecommunications / 1H10 Preview: Shifting Focus to Fixed Line	
S. Korea Technology / Recent LED Correction Provides Attractive Entry Point	
China Economics / Renminbi on Summer Break	

Company/Industry Analysis

Austereo Limited (Australia) / No Joking ... Hamish & Andy Departure Could Prove Negative For EPS ... But No Material Impact On Intrinsic Value	Overweight
iiNet Limited (Australia) / FY10 Result In Line; Near-Term Growth Outlook Dims in Telstra's Shadow	Overweight
Imdex Ltd (Australia) / Fluids Back in Motion	Overweight
Leighton Holdings Ltd. (Australia) / Valuation Attractive for Current Point in the Cycle	Overweight
Anhui Conch Cement Co. Ltd (China) / In-line 2Q10; Maintain EW	Equal-weight
Tingyi (Cayman Islands) (China) / 2Q10: A No Surprise Quarter	Equal-weight
CLP Holdings (Hong Kong) / Turnaround in China and Australia	Equal-weight
China Power / July: Power Demand Slowdown to 13.9% YoY; While 10.7% Growth MoM	
Jinro (S. Korea) / Not Much Upside with Few Catalysts	Equal-weight

Strategy/Economics Analysis

Australia Strategy and Economics / Living in a Bubble

Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of Morgan Stanley Research. Investors should consider Morgan Stanley Research as only a single factor in making their investment decision.

For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report.

+ = Analysts employed by non-U.S. affiliates are not registered with FINRA, may not be associated persons of the member and may not be subject to NASD/NYSE restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

What's Changed

Stock Rating Changes - Downgrades

Ticker	Company	Stock Rating		Price Target		ModelWare Estimate		Consensus*
		From	To	From	To	From	To (FY)	
000080.KS	Jinro	O	E	W40,000	W41,000	W2,661	W2,573(12/10)	--
						W2,949	W2,940(12/11)	--
						W3,383	W3,367(12/12)	--

Estimates/Price Target Changes - Up

2020.HK	ANTA Sports Products	--	O	HK\$13.80	HK\$17.30	Rmb0.58 Rmb0.67 Rmb0.79	Rmb0.59(12/10) Rmb0.70(12/11) Rmb0.82(12/12)	Rmb0.59 Rmb0.72 Rmb0.86
0941.HK	China Mobile Limited	--	E	HK\$88.00	HK\$90.00	Rmb5.94(12/10) Rmb6.13(12/11)	Rmb5.75(12/10) Rmb5.98(12/11)	--
0728.HK	China Telecom	--	E	HK\$3.40	HK\$3.90	Rmb0.20(12/11)	Rmb0.17(12/11)	--
0762.HK	China Unicom	--	O	HK\$12.20	HK\$12.50	Rmb0.21(12/10) Rmb0.23(12/11)	Rmb0.10(12/10) Rmb0.11(12/11)	--
0002.HK	CLP Holdings	--	E	HK\$55.20	HK\$61.34	HK\$3.62 HK\$3.79 HK\$3.95	HK\$3.85(12/10) HK\$4.02(12/11) HK\$4.14(12/12)	HK\$3.64 HK\$3.78 HK\$3.98
LEI.AX	Leighton Holdings Ltd.	--	O	A\$39.25	A\$40.10	--	--	--
0322.HK	Tingyi (Cayman Islands)	--	E	HK\$18.40	HK\$18.50	HK\$0.71 HK\$0.83	HK\$0.72(12/11) HK\$0.84(12/12)	HK\$0.74 HK\$0.90

Estimates/Price Target Changes - Down

011070.KS	LG Innotek	--	O	W220,000	W200,000	--	--	--
009150.KS	Samsung Electro-Mechanics	--	O	W192,000	W183,000	--	--	--

Estimates/Price Target Changes - Up/Down

IIN.AX	iiNet Limited	--	O	A\$3.80	A\$3.50	A\$0.26 A\$0.33	A\$0.28(6/11) A\$0.34(6/12)	A\$0.29 A\$0.35
NCM.AX	Newcrest Mining	--	O	A\$40.63	A\$41.09	A\$1.45 A\$1.63 A\$1.52	A\$1.59(6/10) A\$1.64(6/11) A\$1.49(6/12)	A\$1.40 A\$1.86 A\$2.18

* First Call consensus estimate. For valuation methodology and risks associated with any price targets above, please email morganstanley.research@morganstanley.com with a request for valuation methodology and risks on a particular stock

The Morning Call

NCM.AX, Newcrest Mining (A\$35.20) /Historically NCM Outperforms Gold in 2H of Year

Morgan Stanley Australia Limited

Cameron.Judd@morganstanley.com, Craig.Campbell, Sarah.Lester

Average 4Q return is 18.5% since 2003; Overweight. Although the share price has underperformed the A\$ gold price by 12% year to date, several catalysts could reverse this trend. The stock price typically performed most strongly in 3Q and 4Q of each year. Since 2003, it has returned on average 18.5% in 4Q, vs. the average US\$ gold price return of 7.3%.

LGL shareholders scheduled to vote on NCM's offer August 23. Should the offer be

Rating: Overweight

Australia Gold: Attractive

Target: A\$41.09

52-Week Range: A\$39.75-28.47

Mkt. Cap(mn): A\$17,071

ModelWare EPS: A\$1.59 (FY 6/10), A\$1.64 (FY 6/11)

approved, NCM would assume management control of LGL's assets by August 30. In our view, NCM could re-rate following this event as it brings forward significant growth projects. We would expect buying pressure from domestic institutions who own a relatively small 16% of outstanding shares (international institutions own 69%).

F2010 underlying NPAT A\$764mn: The result was 9% ahead of our estimate and 16% ahead of consensus, and was driven by increased gold production, lower operating costs and higher commodity prices. EBITDA margin in was 51%, versus 41% in F2009. Operating cash flow was A\$1,303mn, 27% higher than F2009.

2020.HK, ANTA Sports Products (HK\$14.98) /1H10 Beat on Margin; Maintain OW
Dennis.Tao@morganstanley.com, Angela.Moh, Jessica.JJ.Wang

Retain Overweight, raise price target to HK\$17.3: Our price target change reflects higher increased earnings estimates for 2010-12. In addition, we have lifted our longer-term earnings forecast given the ongoing enhancement in brand equity and the ensuing more sustainable growth, in our view.

1H net profit of Rmb760 mn, up 25% or 11% above our forecast: The better-than-expected results came from better gross margin and lower operating expenses. More advertising and promotion dollars will be allocated to 2H10 with the recent endorsement of NBA star Kevin Garnett and sponsorship of the Asian Games in Guangzhou. The effective tax rate increased to 20.7% in 1H10 from 14.2% in the same period a year ago, due to the tax holiday expiration at its subsidiaries and the additional dividend withholding tax of 5%.

Raising earnings estimates 2% for 2010 and 4% for 2011-2012: This takes into account better sales and gross margin, partly offset by higher effective tax rates. For the full year 2010, we project net profit growth of 18% to Rmb1,472mn. This implies only modest earnings growth of about 11% in 2H10, reflecting the higher A&P expenses.

Rating: Overweight
China Branded Sports Apparel and Footwear: Attractive
Target: HK\$17.30
52-Week Range: HK\$15.48-9.14
Mkt. Cap(mn): Rmb32,603
ModelWare EPS: Rmb0.59 (FY 12/10), Rmb0.70 (FY 12/11)

China Telecommunications: 1H10 Preview: Shifting Focus to Fixed Line

Navin.Killa@morganstanley.com, Gary.H.Yu, Yvonne.Chow

China Telecommunications: In-Line

Retain In-Line industry view; China Unicom still our preferred name. We expect interim results overall to come in strong, as mobile competition has not worsened much, and mobile revenue will continue to benefit from an improved macro environment.

Results will likely turn the market's focus back to fixed line segment. The proposed "three network convergence" (TNC) initiatives from the government create medium-term risks. We see risks of pre-emptive capex increases, broadband tariff cuts and higher marketing spend from the fixed line operators in anticipation of competition from cable companies in 2-3 years.

Stock thesis: China Unicom (0762.HK, HK\$.50, O) is our preferred pick, as we remain believers in its 3G technology advantage. CU's 3G business has continued to show steady momentum with monthly net adds reaching 1mn for the past two months. We also expect the fixed line business to show steady performance in 1H10. We stay Equal-weight on China Mobile (0941.HK, HK\$83.70) and China Telecom (0728.HK, HK\$3.79) with a relative preference for the former. (See our published report for details, including changes to our EPS forecasts and price targets.).

S. Korea Technology: Recent LED Correction Provides Attractive Entry Point

Morgan Stanley & Co. International plc, Seoul Branch

Young.Shin@morganstanley.com, Keon.Han, Mike.Chung

S. Korea Technology: In-Line

Remain positive on global LED market outlook. Despite a recent slowdown in LED order momentum on global LCD TV inventory adjustments, our channel checks indicate that industry

dynamics remain skewed to the suppliers' side. We continue to view the recent slowdown as a temporary hiccup of a newly growing industry. Barring any significant macro slowdown impacting LED TV demand outlook, we think oversupply concerns are premature and expect healthy earnings growth to continue

Accumulate LED names. We believe the recent share price correction is overdone and recommend that investors accumulate LED names. We maintain our Overweight rating on SEMCO (009150.KS, W129,500) and view the recent share 19% correction as excessive. Our new price target implies 41% upside. We also stay Overweight LG Innotek's (011070.KS, W146,000) and view its 24% correction as excessive. Our revised target price of W200,000 implies 37% upside.

Overall LED momentum should resume by September. We think LED TV makers, particularly in Korea, will aggressively promote LED TVs in 2H10 as the window of opportunity to charge a premium on LED TVs will narrow in the next one year or so. We expect strong demand and limited ASP erosion to prevent any sharp margin erosion for the Korean LED makers.

China Economics/Renminbi on Summer Break

Qing.Wang@morganstanley.com

Currency update: Since it exited from its peg against the US\$ on June 20, the Renminbi has appreciated vs the US\$ rather fast (~0.8% in the first 10 trading days through July 2). However, the US\$/CNY rate has since been broadly stable at around 6.77, while most other EM currencies have registered meaningful appreciation against the US\$.

Chinese authorities have recently launched an educational campaign articulating the virtues of and their strong commitment to a flexible FX arrangement in the form of five consecutive articles published under the name of PBoC Deputy Governor Hu Xiaolian. This is the first time that Chinese authorities systematically address several important issues pertinent to China's exchange rate policy.

What's next: Authorities will likely more proactively put their strategy of pursuing a flexible FX rate arrangement into action by: a) allowing faster appreciation of Renminbi vs the US\$ in part to ease political tensions (especially vis-à-vis the US); b) such that Renminbi would appreciate on a trade-weighted basis meaningfully as long as large trade surpluses (i.e., over 2.0% of GDP) persist; and c) imparting more transparency to the operation of currency basket by officially publishing the nominal effective exchange rate index for Renminbi. We maintain our forecast that the US\$/CNY rate will reach 6.60 by end-2010 and 6.20 by end-2011.

Company/Industry Analysis

AUSTRALIA

AEO.AX, Austereo Limited (A\$1.77) /No Joking ... Hamish & Andy Departure Could Prove Negative For EPS ... But No Material Impact On Intrinsic Value

Morgan Stanley Australia Limited

Andrew.Mcleod@morganstanley.com, Mark.Goodridge

Conclusion: We see a larger than typical earnings risk on the horizon with national drive-time *The Hamish & Andy Show* yet to decide whether they will extend their run beyond this year. In radio, typically the 'drive' time period doesn't garner the same audiences or advertising dollars as "Breakfast" ... because the comedy duo Hamish & Andy are: 1) uniquely dominant in their

Rating: Overweight

Australia Media: In-Line

Target: A\$2.00

52-Week Range: A\$1.93-1.27

Mkt. Cap(mn): A\$610

ModelWare EPS: A\$0.16 (FY 6/'11), A\$0.17 (FY 6/'12)

timeslot; and, 2) networked nationally across five capital cities ... it is financially significant.

We estimate this time slot may generate A\$30-40m revenue and A\$10-15m EBITDA annually. Hypothetically, if the show were to end, whilst the downside could be ameliorated with a lower cost replacement, we still estimate the potential EPS risk to be in the range -5% to -10% for the first 12 months. More important, the DCF impact would be a lesser negative 3c-5c/AEO share (i.e. 2-3%) assuming it takes 2 years to develop a replacement show, with audience ratings at 75% of current levels.

F2010 results in-line. A strong start to 1H provides increased confidence for F2011E EPS/DPS growth. Reported EPS of 13.7c vs. 13.1c in pcp, our est.14.0c. The radio ad market recovered strongly in 2H, up 7% and AEO delivered a 2H EPS lift of 12%. We view AEO stock as attractive, at F2011e P/E of 11x (vs. the long-term average of 15x) with a 6.5% dividend yield (70% payout).

IIN.AX, iiNet Limited (A\$2.68) /FY10 Result In Line; Near-Term Growth Outlook Dims in Telstra's Shadow

Morgan Stanley Australia Limited

Mark.Blackwell@morganstanley.com

Morgan Stanley Asia Limited

Navin.Killa@morganstanley.com

Rating: Overweight

Australia/NZ Telecommunications:

In-Line

Target: A\$3.50

52-Week Range: A\$3.13-1.67

Mkt. Cap(mn): A\$406

ModelWare EPS: A\$0.28 (FY 6/'11), A\$0.34

(FY 6/'12)

Still value in iiNet's tangible longer-term growth path, but may be harder to find near term.

We see at least four key reasons why Telstra is unlikely to win back significant share in broadband, however: 1) The mobile market opportunity is more attractive; 2) Telstra's broadband prices remain more expensive, with less satisfactory customer service; 3) Telstra will likely fare worse in a flat broadband market, with relatively more churning customers, and 4) Telstra may be obliged to match retail price reductions for wholesale customers, diminishing the competitive value of price cuts. Market share gains by iiNet and others may be harder to find, though, and we have lowered our customer and earnings growth forecasts accordingly.

What's new: The F2011 EBITDA outlook statement was muted at A\$106mn. After the impact of Netspace and AAPT acquisitions, guidance implies no organic growth vs F2010. iiNet's F2010 result headlines were pre-announced to the market at the time of the AAPT acquisition announcement: F2010 EBITDA and NPAT were A\$80.7mn and A\$34.8mn, respectively (after one-off adjustments). We had forecast NPAT of A\$28.5mn, and consensus was \$30.1mn.

What's next: Telstra plans to outline its growth strategy at a Strategy Day in October. Telstra may choose to provide more detail about the markets it expects to fuel its longer-term growth ambitions, and investors will have an opportunity to stress-test Telstra's growth ambitions.

IMD.AX, Imdex Ltd (A\$0.84) /Fluids Back in Motion

Morgan Stanley Australia Limited

David.Evans@morganstanley.com, Chris.Nicol, James.Bales

Rating: Overweight

Australia Emerging Companies: In-Line

Target: A\$1.20

52-Week Range: A\$0.96-0.53

Mkt. Cap(mn): A\$164

ModelWare EPS: A\$0.09 (FY 6/'11), A\$0.12

(FY 6/'12)

Reiterate Overweight. F2010 results demonstrated not only that the company had negotiated the global downturn but also that the rate of recovery has Imdex positioned for an expansive future, with 4Q10 revenue close to a record and June a record month.

F2010 results overview: Imdex reported F2010 revenue of A\$134.3mn and EBITA of A\$20.7mn. More significant, 4Q revenue was A\$42.9mn and EBITA A\$8.0mn, representing 32% and 39% respectively of full year, at a margin of 18.6%.

Estimate changes: We raise our F2011 forecasts by 3% at the revenue line. EBITA forecasts are 6.1% higher to A\$32.8mn, a slightly higher margin of 21.2%, while NPAT forecasts move up slightly after allowing for a higher tax rate. Our F2012 forecasts are broadly unchanged. With continued strength in minerals activity apparent in the mid-term and potential for an expansion

into oil & gas longer-term, we reiterate our Overweight rating.

LEI.AX, Leighton Holdings Ltd. (A\$30.60) /Valuation Attractive for Current Point in the Cycle

Morgan Stanley Australia Limited
Andrew.Moller@morganstanley.com

Solid F2010 results; Price target up, remain Overweight. Leighton reported F2010 earnings that were largely in line with expectations, while strong work in hand and favorable outlook statements were a clear positive.

Key highlights: F2010 earnings of A\$612mn were largely in line with consensus/our estimates. WIH rose to a record A\$41.5bn, the top end of prior guidance and ahead of expectations. Contract wins post June-30 are likely to mean the order book is currently above A\$42bn. Fully franked final dividend of 85c was declared (73% payout ratio), ahead of our 65c expectation. Operating cash flow rose to A\$1.7bn from A\$875.9mn and gearing fell to 38% (including off balance sheet leases) from 48% removing the risk of a near term equity raising, in our view.

Attractive valuation: Our A\$40.10 DCF suggests ~30% upside, with Leighton trading at 13.4x P/E (one year forward consensus), a 12% discount its historical long term average of 15.2x, despite forecast EPS growth of 10.7% and 10.5%, for F2011 and F2012, respectively. Long term growth drivers include: (1) Resource demand from China and recovery of traditional export markets; (2) Infrastructure investment driven by aggressive state and federal government plans; and (3) Offshore expansion in emerging markets poised to grow during recovery.

Rating: Overweight
Australia Capital Goods: Attractive
Target: A\$40.10
52-Week Range: A\$41.70-27.61
Mkt. Cap(mn): A\$9,275
ModelWare EPS: A\$2.25 (FY 6/11), A\$2.48 (FY 6/12)

CHINA

0914.HK, Anhui Conch Cement Co. Ltd (HK\$26.20) /In-line 2Q10; Maintain EW

Morgan Stanley Asia Limited
Sandy.Niu@morganstanley.com, John.Lam

Morgan Stanley Asia (Singapore) Pte.
Charles.Spencer@morganstanley.com

2Q10 results in-line; EPS, price target unchanged; Remain Equal-weight. 2Q EPS of Rmb0.28 was 4% below our forecast of Rmb0.30 but 20% below consensus of Rmb0.35. While GP/ton of Rmb57 was exactly in line, sales volume of 35mn tons was 5% below our estimate, resulting in total gross profit 5% below. Although lower SG&A has resulted in 4% higher EBIT, higher finance cost and income tax brought it back to an in-line bottom line at Rmb1bn.

Capacity expansion on track. In 1H, the company completed construction for 7 clinker lines and 12 cement grinding stations in Sichuan, Gansu and Jiangxi, increasing clinker and cement capacity by 12.6mn tons and 13.2mn tons, respectively, on track with guidance of a 29mnt increase in clinker capacity this year. Looking into 2H, the company will continue to develop new projects and proceed with acquisitions to sustain market share growth.

Positive industry outlook: The company maintains its positive 2H view, on strong demand from infrastructure, social housing, and development in Western China, as well as accelerated closure of outdated capacity. On 8 August, MIIT announced a detailed closure list, which contains 762 producers with 107mnt capacity (~5% of 2010e capacity) to be closed by 3Q10, suggesting an improving demand-supply dynamics.

Funds managed by Morgan Stanley, beneficially own, in aggregate, approximately 9% or more of a class of securities and have appointed a director to hold a board seat in China Shanshui Cement

Rating: Equal-weight
China Building Materials: Attractive
Target: HK\$28.00
52-Week Range: HK\$29.60-21.45
Mkt. Cap(mn): US\$11,910
ModelWare EPS: Rmb1.35 (FY 12/10), Rmb1.69 (FY 12/11)

0322.HK, Tingyi (Cayman Islands) (HK\$18.64) /2Q10: A No Surprise Quarter

Rating: Equal-weight

Angela.Moh@morganstanley.com, Penny.Tu

Maintain Equal-weight, price target of HK\$18.5: Our thesis is unchanged after 2Q results; sales should remain robust in the rest of 2010 and long-term growth prospects are still solid, while some margin pressure could come from both higher input cost and intense competition. At 31.6x 2010E P/E or 25.9x 2011E P/E, we feel risk-reward is not attractive and would wait for better entry point.

2Q: Strong beverage sales but opex also higher. 2Q net profit came in at US\$95 mn (up 10%), in line with our estimate of US\$98 mn. While sales growth of 35% was 9% higher than our expectation due to strong beverage sales, operating profit growth of 15% was in-line on higher selling expense from promotions.

Earnings revisions. We leave our 2010-11 estimates largely unchanged after the following adjustments: 1) bumping up noodle and beverage sales to factor in better sales momentum thus far; 2) trimming gross margin assumptions to leave more buffer for high input cost; 3) slightly higher operating expense from promotions..

China Food, Bev. & Tobacco: Attractive
Target: HK\$18.50
52-Week Range: HK\$20.60-13.52
Mkt. Cap(mn): HK\$104,328
ModelWare EPS: HK\$0.59 (FY 12/'10), HK\$0.72 (FY 12/'11)

HONG KONG

0002.HK, CLP Holdings (HK\$58.05) /Turnaround in China and Australia

Simon.Lee@morganstanley.com, Joseph.C.Lam

1H10 results update; Remain Equal-weight. 1H net profit of HK\$5.921bn was up 83% YoY. Excluding one-off gains, recurring net earnings rose 26.6% due to a turnaround from the loss of Chinese IPPs and >100% earnings growth in Australia on operational improvement. We believe CLP is now on track to deliver consistent earnings growth from 2010. With an increase in capex in Hong Kong (up 16% YoY) and a stable dividend payout but reduced SOC return, there could be less cash flow available to fund overseas, and we believe CLP's medium-term earnings growth will depend largely on execution of the more visible investment opportunities in HK, China, and India, with a focus on renewable projects.

CLP is negotiating terms on its 17% stake in CGNPC's 6GW Yangjiang Nuclear Project. We believe the consideration CLP will pay to CGNPC will be very close to CGNPC's original cost. Earnings quality for Yangjiang is high as the on-grid power tariff under the feasibility study is very competitive at Rmb363/MWh, compared to the average coal-fired on-grid tariff at Guangdong at Rmb504.2/MWh.

Investment thesis: CLP trades at 14.4x our 2011E P/E and 8.8x EV/EBITDA and offers a 4.5% dividend yield. We have revised our estimates on our latest currency and economic forecasts, as well as improved operation in China and Australia. Among HK utilities CKI (1038.HK, HK\$30, O) is our top pick given its highest dividend yield, discount to NAV, and acquisition growth potential.

Rating: Equal-weight
Hong Kong Utilities: In-Line
Target: HK\$61.34
52-Week Range: HK\$58.05-51.60
Mkt. Cap(mn): HK\$139,677
ModelWare EPS: HK\$3.85 (FY 12/'10), HK\$4.02 (FY 12/'11)

China Power: July: Power Demand Slowdown to 13.9% YoY; While 10.7% Growth MoM

Simon.Lee@morganstanley.com, Eva.Hou

Julypower demand down slightly to 13.9% YoY, from 14.1% in June. While the YoY growth rate declined 0.2bbp, monthly power demand edged up by 10.7% MoM in July, compared to a modest 1.1% increase last month. We note that the secondary demand growth of 15.4% MoM drives the total demand growth, followed by demand from residential of 20.1% and from tertiary industry of 15.7% due to the seasonally effect. From January-July, total power demand amounted to 2,399bn kWh, up 20.3% YoY but continued to slow from 21.6% in the 1H10.

What's new: Huaneng (0902.HK, HK\$4.71, E) reported 1H10 results last week. Despite a slightly better-than-expected result and earnings growth in 2Q QoQ, we note that both the gross

China Power: In-Line

margin and EBIT margin further deteriorated in the second quarter due to the coal price increase. Datang (0991.HK, HK\$3.18, E) will release 1H10 results this week. We expect a positive surprise from its hydro power plants but overall earnings should be under pressure.

Investment thesis: In 2010, we believe coastal IPPs such as Huaneng and CRP (0836.HK, HK\$17.50, O) will be better than inland IPPs such as Huadian and Datang. We reiterate CRP as our only Overweight in China IPPs, given its power plant enjoys the highest exposure to the coastal area.

S. KOREA

000080.KS, Jinro (W37,750) /Not Much Upside with Few Catalysts

Morgan Stanley & Co. International plc, Seoul Branch

Kelly.Kim@morganstanley.com, Jenna.Mok

Morgan Stanley Asia Limited

Angela.Moh@morganstanley.com

Rating: Equal-weight

S. Korea Consumer: In-Line

Target: W41,000

52-Week Range: W44,650-30,150

Mkt. Cap(bn): W1,604

ModelWare EPS: W2,573 (FY 12/'10), W2,940 (FY 12/'11)

Downgrade to Equal-weight. Although a base-year shift lifts our price target slightly to W41,000, strong recent stock performance does not allow much upside from current levels. Due to the high base effect from 2009, we expect earnings momentum could remain weak in 3Q10. We believe 4Q10 could be a better time to revisit the name, ahead of dividend announcement, outlook for a strong earnings pickup, and a visible plan for co-marketing efforts with Hite Brewery.

2Q weaker than expected. Net income was roughly in line with our estimates, but operating income was much lower than expected. We believe weak volume in the soju market (we estimate down around 5-6% YoY) and a high base in Jinro's market share (around 49% in 2Q10 vs. 51.3% in 2Q09) led overall sales to decline -8.6% YoY. A high proportion of fixed costs and rising A&P costs dampened OPM by 5.9ppt compared to last year.

Still challenging base in 3Q10: Last year, Jinro had an aggressive inventory push at the wholesale level, driving overall market growth of +3.7% YoY. We expect this challenging base effect could lead to a volume decline with operating margin contraction again in 3Q10.

Strategy/Economics Analysis

Australia Strategy and Economics/Living in a Bubble

Morgan Stanley Australia Limited

Gerard.Minack@morganstanley.com

Australia's debt-fuelled housing market remains a major macro risk. Dodging the worst of the global financial crisis didn't demonstrate that there's no bubble; in my view it just showed we dodged the prick. I'm not persuaded by arguments that houses are sustainably priced; I'm not persuaded by the view that debt is not a problem; and I'm not persuaded that policy-makers could prevent collateral damage to banks. However, the risk of big price declines in the near term seems low.

In my view, Australian house prices are expensive on every value metric. They are expensive relative to history, and expensive relative to houses in comparable countries. Most measures suggest house prices are around 40% above fair value. There's a word for a financial asset that's over-valued by 40%, so let's use it: housing is a bubble. Buying an asset that's over-priced never ends well. The real return on residential property over the next decade is likely to be negative, in my view.

Valuation measures are broadly consistent about the degree of over-valuation. They're

also consistent about when the bubble started to inflate: from around 2000. What caused the bubble? The key is the growing ability and willingness of Australians to increase leverage, compounded by what I would view as ill-advised policy (such as grants to first home-buyers). Owner-occupiers have played a game of financial chicken, competing for property by taking on increasingly imprudent amounts of debt. Investors have become Ponzi borrowers – Hyman Minsky’s term for borrowers who rely on capital gains to repay debt and interest – in the belief that housing is a sure-fire long-term investment. History shows that it isn’t.

What will prick the bubble? The most plausible trigger is broad-based jobs losses. That doesn’t appear likely in the near-term (although global risks are rising). Other, more imminent, risks include banks tightening credit and/or Australia’s army of loss-making middle-class landlords starting to sell.

Disclosure Section

The information and opinions in Morgan Stanley Research were prepared or are disseminated by Morgan Stanley Asia Limited (which accepts the responsibility for its contents) and/or Morgan Stanley Asia (Singapore) Pte. (Registration number 199206298Z, regulated by the Monetary Authority of Singapore, which accepts the responsibility for its contents), and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H, regulated by the Monetary Authority of Singapore, which accepts the responsibility for its contents), and/or Morgan Stanley Taiwan Limited and/or Morgan Stanley & Co International plc, Seoul Branch, and/or Morgan Stanley Australia Limited (A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents), and/or Morgan Stanley Smith Barney Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian financial services license No. 240813, which accepts responsibility for its contents), and/or Morgan Stanley India Company Private Limited and their affiliates (collectively, "Morgan Stanley").

For important disclosures, stock price charts and equity rating histories regarding companies that are the subject of this report, please see the Morgan Stanley Research Disclosure Website at www.morganstanley.com/researchdisclosures, or contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY, 10036 USA.

Analyst Certification

As to each company mentioned in this report, the respective primary research analyst or analysts covering that company hereby certify that their views about the companies and their securities discussed in this report are accurately expressed and that they have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report.

Global Research Conflict Management Policy

Morgan Stanley Research has been published in accordance with our conflict management policy, which is available at www.morganstanley.com/institutional/research/conflictolicies.

Important US Regulatory Disclosures on Subject Companies

As of July 30, 2010, Morgan Stanley beneficially owned 1% or more of a class of common equity securities of the following companies covered in Morgan Stanley Research: China Resources Power, China Telecom, LG Innotek, Lihir.

Within the last 12 months, Morgan Stanley managed or co-managed a public offering (or 144A offering) of securities of ANTA Sports Products, China Resources Power, Samsung Life Insurance.

Within the last 12 months, Morgan Stanley has received compensation for investment banking services from ANTA Sports Products, China Resources Power, Samsung Life Insurance.

In the next 3 months, Morgan Stanley expects to receive or intends to seek compensation for investment banking services from Anhui Conch Cement Co. Ltd, Cheung Kong Infra., China Mobile Limited, China Resources Power, China Telecom, CLP Holdings, Datang Int'l Power, Huadian Power Int'l, Huaneng Power, iiNet Limited, Newcrest Mining, Samsung Life Insurance.

Within the last 12 months, Morgan Stanley has received compensation for products and services other than investment banking services from Samsung Life Insurance.

Within the last 12 months, Morgan Stanley has provided or is providing investment banking services to, or has an investment banking client relationship with, the following company: Anhui Conch Cement Co. Ltd, ANTA Sports Products, Cheung Kong Infra., China Mobile Limited, China Resources Power, China Telecom, CLP Holdings, Datang Int'l Power, Huadian Power Int'l, Huaneng Power, iiNet Limited, Newcrest Mining, Samsung Life Insurance.

Within the last 12 months, Morgan Stanley has either provided or is providing non-investment banking, securities-related services to and/or in the past has entered into an agreement to provide services or has a client relationship with the following company: China Unicom, Hite Brewery, Hite Holdings, Newcrest Mining, Samsung Life Insurance.

The equity research analysts or strategists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment banking revenues.

Morgan Stanley and its affiliates do business that relates to companies/instruments covered in Morgan Stanley Research, including market making, providing liquidity and specialized trading, risk arbitrage and other proprietary trading, fund management, commercial banking, extension of credit, investment services and investment banking. Morgan Stanley sells to and buys from customers the securities/instruments of companies covered in Morgan Stanley Research on a principal basis. Morgan Stanley may have a position in the debt of the Company or instruments discussed in this report.

Certain disclosures listed above are also for compliance with applicable regulations in non-US jurisdictions.

STOCK RATINGS

Morgan Stanley uses a relative rating system using terms such as Overweight, Equal-weight, Not-Rated or Underweight (see definitions below). Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold and sell. Investors should carefully read the definitions of all ratings used in Morgan Stanley Research. In addition, since Morgan Stanley Research contains more complete information concerning the analyst's views, investors should carefully read Morgan Stanley Research, in its entirety, and not infer the contents from the rating alone. In any case, ratings (or research) should not be used or relied upon as investment advice. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations.

Global Stock Ratings Distribution

(as of July 31, 2010)

For disclosure purposes only (in accordance with NASD and NYSE requirements), we include the category headings of Buy, Hold, and Sell alongside our ratings of Overweight, Equal-weight, Not-Rated and Underweight. Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold, and sell but represent recommended relative weightings (see definitions below). To satisfy regulatory requirements, we correspond Overweight, our most positive stock rating, with a buy recommendation; we correspond Equal-weight and Not-Rated to hold and Underweight to sell recommendations, respectively.

Stock Rating Category	Coverage Universe		Investment Banking Clients (IBC)		
	Count	% of Total	Count	% of Total IBC	% of Rating Category
Overweight/Buy	1095	42%	380	44%	35%
Equal-weight/Hold	1123	43%	388	45%	35%
Not-Rated/Hold	14	1%	4	0%	29%
Underweight/Sell	362	14%	93	11%	26%
Total	2,594		865		

Data include common stock and ADRs currently assigned ratings. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations. Investment Banking Clients are companies from whom Morgan Stanley received investment banking compensation in the last 12 months.

Analyst Stock Ratings

Overweight (O or Over) - The stock's total return is expected to exceed the total return of the relevant country MSCI Index, on a risk-adjusted basis over the next 12-18 months.

Equal-weight (E or Equal) - The stock's total return is expected to be in line with the total return of the relevant country MSCI Index, on a risk-adjusted basis over the next 12-18 months.

Not-Rated (NR) - Currently the analyst does not have adequate conviction about the stock's total return relative to the relevant country MSCI Index on a risk-adjusted basis, over the next 12-18 months.

Underweight (U or Under) - The stock's total return is expected to be below the total return of the relevant country MSCI Index, on a risk-adjusted basis, over the next 12-18 months.

Unless otherwise specified, the time frame for price targets included in Morgan Stanley Research is 12 to 18 months.

For Australian Property stocks, each stock's total return is benchmarked against the average total return of the analyst's industry (or industry team's) coverage universe, instead of the relevant country MSCI Index, on a risk-adjusted basis, over the next 12-18 months.

Analyst Industry Views

Attractive (A): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be attractive vs. the relevant broad market benchmark, as indicated below.

In-Line (I): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be in line with the relevant broad market benchmark, as indicated below.

Cautious (C): The analyst views the performance of his or her industry coverage universe over the next 12-18 months with caution vs. the relevant broad market benchmark, as indicated below.

Benchmarks for each region are as follows: North America - S&P 500; Latin America - relevant MSCI country index or MSCI Latin America Index; Europe - MSCI Europe; Japan - TOPIX; Asia - relevant MSCI country index.

Important Disclosures for Morgan Stanley Smith Barney LLC Customers

Citi Investment Research & Analysis (CIRA) research reports may be available about the companies or topics that are the subject of Morgan Stanley Research. Ask your Financial Advisor or use Research Center to view any available CIRA research reports in addition to Morgan Stanley research reports.

Important disclosures regarding the relationship between the companies that are the subject of Morgan Stanley Research and Morgan Stanley Smith Barney LLC, Morgan Stanley and Citigroup Global Markets Inc. or any of their affiliates, are available on the Morgan Stanley Smith Barney disclosure website at www.morganstanleysmithbarney.com/researchdisclosures.

For Morgan Stanley and Citigroup Global Markets, Inc. specific disclosures, you may refer to www.morganstanley.com/researchdisclosures and https://www.citigroupgeo.com/geopublic/Disclosures/index_a.html.

Each Morgan Stanley Equity Research report is reviewed and approved on behalf of Morgan Stanley Smith Barney LLC. This review and approval is conducted by the same person who reviews the Equity Research report on behalf of Morgan Stanley. This could create a conflict of interest.

Other Important Disclosures

Morgan Stanley & Co. International PLC and its affiliates have a significant financial interest in the debt securities of China Mobile Limited, China Resources Power, CLP Holdings.

Morgan Stanley produces an equity research product called a "Tactical Idea." Views contained in a "Tactical Idea" on a particular stock may be contrary to the recommendations or views expressed in research on the same stock. This may be the result of differing time horizons, methodologies, market events, or other factors. For all research available on a particular stock, please contact your sales representative or go to Client Link at www.morganstanley.com.

Morgan Stanley Research does not provide individually tailored investment advice. Morgan Stanley Research has been prepared without regard to the individual financial circumstances and objectives of persons who receive it. Morgan Stanley recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of a particular investment or strategy will depend on an investor's individual circumstances and objectives. The securities, instruments, or strategies discussed in Morgan Stanley Research may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them.

The fixed income research analysts or strategists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality, accuracy and value of research, firm profitability or revenues (which include fixed income trading and capital markets profitability or revenues), client feedback and competitive factors. Fixed Income Research analysts' or strategists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

Morgan Stanley Research is not an offer to buy or sell or the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy. The "Important US Regulatory Disclosures on Subject Companies" section in Morgan Stanley Research lists all companies mentioned where Morgan Stanley owns 1% or more of a class of common equity securities of the companies. For all other companies mentioned in Morgan Stanley Research, Morgan Stanley may have an investment of less than 1% in securities/instruments or derivatives of securities/instruments of companies and may trade them in ways different from those discussed in Morgan Stanley Research. Employees of Morgan Stanley not involved in the preparation of Morgan Stanley Research may have investments in securities/instruments or derivatives of securities/instruments of companies mentioned and may trade them in ways different from those discussed in Morgan Stanley Research. Derivatives may be issued by Morgan Stanley or associated persons.

With the exception of information regarding Morgan Stanley, Morgan Stanley Research is based on public information. Morgan Stanley makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or information in Morgan Stanley Research change apart from when we intend to discontinue equity research coverage of a subject company. Facts and views presented in Morgan Stanley Research have not been reviewed by, and may not reflect information known to, professionals in other Morgan Stanley business areas, including investment banking personnel.

Morgan Stanley Research personnel may participate in company events such as site visits and are generally prohibited from accepting payment by the company of associated expenses unless pre-approved by authorized members of Research management.

The value of and income from your investments may vary because of changes in interest rates, foreign exchange rates, default rates, prepayment rates, securities/instruments prices, market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in securities/instruments transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. If provided, and unless otherwise stated, the closing price on the cover page is that of the primary exchange for the subject company's securities/instruments.

Morgan Stanley may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

To our readers in Taiwan: Information on securities/instruments that trade in Taiwan is distributed by Morgan Stanley Taiwan Limited ("MSTL"). Such information is for your reference only. Information on any securities/instruments issued by a company owned by the government of or incorporated in the PRC and listed in on the Stock Exchange of Hong Kong ("SEHK"), namely the H-shares, including the component company stocks of the Stock Exchange of Hong Kong ("SEHK")'s Hang Seng China Enterprise Index; or any securities/instruments issued by a company that is 30% or more directly- or indirectly-owned by the government of or a company incorporated in the PRC and traded on an exchange in Hong Kong or Macau, namely SEHK's Red Chip shares, including the component company of the SEHK's China-affiliated Corp Index is distributed only to Taiwan Securities Investment Trust Enterprises ("SITE"). The reader should independently evaluate the investment risks and is solely responsible for their investment decisions. Morgan Stanley Research may not be distributed to the public media or quoted or used by the public media without the express written consent of Morgan Stanley. Information on securities/instruments that do not

trade in Taiwan is for informational purposes only and is not to be construed as a recommendation or a solicitation to trade in such securities/instruments. MSTL may not execute transactions for clients in these securities/instruments.

To our readers in Hong Kong: Information is distributed in Hong Kong by and on behalf of, and is attributable to, Morgan Stanley Asia Limited as part of its regulated activities in Hong Kong. If you have any queries concerning Morgan Stanley Research, please contact our Hong Kong sales representatives.

Certain information in Morgan Stanley Research was sourced by employees of the Shanghai Representative Office of Morgan Stanley Asia Limited for the use of Morgan Stanley Asia Limited.

Morgan Stanley Research is disseminated in Japan by Morgan Stanley MUFG Securities Co., Ltd.; in Hong Kong by Morgan Stanley Asia Limited (which accepts responsibility for its contents); in Singapore by Morgan Stanley Asia (Singapore) Pte. (Registration number 199206298Z) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore, which accepts responsibility for its contents; in Australia to "wholesale clients" within the meaning of the Australian Corporations Act by Morgan Stanley Australia Limited A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents; in Australia to "wholesale clients" and "retail clients" within the meaning of the Australian Corporations Act by Morgan Stanley Smith Barney Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian financial services license No. 240813, which accepts responsibility for its contents; in Korea by Morgan Stanley & Co International plc, Seoul Branch; in India by Morgan Stanley India Company Private Limited; in Canada by Morgan Stanley Canada Limited, which has approved of, and has agreed to take responsibility for, the contents of Morgan Stanley Research in Canada; in Germany by Morgan Stanley Bank AG, Frankfurt am Main and Morgan Stanley Private Wealth Management Limited, Niederlassung Deutschland, regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin); in Spain by Morgan Stanley, S.V., S.A., a Morgan Stanley group company, which is supervised by the Spanish Securities Markets Commission (CNMV) and states that Morgan Stanley Research has been written and distributed in accordance with the rules of conduct applicable to financial research as established under Spanish regulations; in the United States by Morgan Stanley & Co. Incorporated, which accepts responsibility for its contents. Morgan Stanley & Co. International plc, authorized and regulated by the Financial Services Authority, disseminates in the UK research that it has prepared, and approves solely for the purposes of section 21 of the Financial Services and Markets Act 2000, research which has been prepared by any of its affiliates. Morgan Stanley Private Wealth Management Limited, authorized and regulated by the Financial Services Authority, also disseminates Morgan Stanley Research in the UK. Private U.K. investors should obtain the advice of their Morgan Stanley & Co. International plc or Morgan Stanley Private Wealth Management representative about the investments concerned. RMB Morgan Stanley (Proprietary) Limited is a member of the JSE Limited and regulated by the Financial Services Board in South Africa. RMB Morgan Stanley (Proprietary) Limited is a joint venture owned equally by Morgan Stanley International Holdings Inc. and RMB Investment Advisory (Proprietary) Limited, which is wholly owned by FirstRand Limited.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (DIFC Branch), regulated by the Dubai Financial Services Authority (the DFSA), and is directed at Professional Clients only, as defined by the DFSA. The financial products or financial services to which this research relates will only be made available to a customer who we are satisfied meets the regulatory criteria to be a Professional Client.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (QFC Branch), regulated by the Qatar Financial Centre Regulatory Authority (the QFCRA), and is directed at business customers and market counterparties only and is not intended for Retail Customers as defined by the QFCRA.

As required by the Capital Markets Board of Turkey, investment information, comments and recommendations stated here, are not within the scope of investment advisory activity. Investment advisory service is provided in accordance with a contract of engagement on investment advisory concluded between brokerage houses, portfolio management companies, non-deposit banks and clients. Comments and recommendations stated here rely on the individual opinions of the ones providing these comments and recommendations. These opinions may not fit to your financial status, risk and return preferences. For this reason, to make an investment decision by relying solely to this information stated here may not bring about outcomes that fit your expectations.

The trademarks and service marks contained in Morgan Stanley Research are the property of their respective owners. Third-party data providers make no warranties or representations of any kind relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages of any kind relating to such data. The Global Industry Classification Standard ("GICS") was developed by and is the exclusive property of MSCI and S&P.

Morgan Stanley has based its projections, opinions, forecasts and trading strategies regarding the MSCI Country Index Series solely on publicly available information. MSCI has not reviewed, approved or endorsed the projections, opinions, forecasts and trading strategies contained herein. Morgan Stanley has no influence on or control over MSCI's index compilation decisions.

Morgan Stanley Research, or any portion thereof may not be reprinted, sold or redistributed without the written consent of Morgan Stanley.

Morgan Stanley Research is disseminated and available primarily electronically, and, in some cases, in printed form.

Additional information on recommended securities/instruments is available on request.

The Americas

1585 Broadway
New York, NY 10036-8293

United States

Tel: +1 (1) 212 761 4000

Europe

20 Bank Street, Canary Wharf
London E14 4AD

United Kingdom

Tel: +44 (0) 20 7 425 8000

Japan

4-20-3 Ebisu, Shibuya-ku
Tokyo 150-6008

Japan

Tel: +81 (0) 3 5424 5000

Asia/Pacific

1 Austin Road West
Kowloon

Hong Kong

Tel: +852 2848 5200